These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 32691670)
21. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. Andrilla CHA; Moore TE; Patterson DG; Larson EH J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637 [TBL] [Abstract][Full Text] [Related]
22. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Lister JJ; Weaver A; Ellis JD; Himle JA; Ledgerwood DM Am J Drug Alcohol Abuse; 2020 May; 46(3):273-288. PubMed ID: 31809217 [TBL] [Abstract][Full Text] [Related]
23. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access. Trigg BG; Dickman SL Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716 [TBL] [Abstract][Full Text] [Related]
24. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians. Andrilla CHA; Moore TE; Patterson DG J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720 [TBL] [Abstract][Full Text] [Related]
25. "The elephant in the room;" a qualitative study of perinatal fears in opioid use disorder treatment in Southern Appalachia. Leiner C; Cody T; Mullins N; Ramage M; Ostrach BMM BMC Pregnancy Childbirth; 2021 Feb; 21(1):143. PubMed ID: 33596843 [TBL] [Abstract][Full Text] [Related]
26. Eight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum. Lien IC; Seaton R; Szpytman A; Chou J; Webber V; Waineo E; Levine D Med Educ Online; 2021 Dec; 26(1):1847755. PubMed ID: 33222656 [No Abstract] [Full Text] [Related]
27. Community Attitudes Toward Opioid Use Disorder and Medication for Opioid Use Disorder in a Rural Appalachian County. Beachler T; Zeller TA; Heo M; Lanzillotta-Rangeley J; Litwin AH J Rural Health; 2021 Jan; 37(1):29-34. PubMed ID: 32738095 [TBL] [Abstract][Full Text] [Related]
28. Systematic content analysis of patient evaluations of START NOW psychotherapy reveals practical strategies for improving the treatment of opioid use disorder. Truong AY; Saway BF; Bouzaher MH; Rasheed MN; Monjazeb S; Everest SD; Giampalmo SL; Hartman D; Hartman C; Kablinger AS; Trestman RL BMC Psychiatry; 2021 Jan; 21(1):23. PubMed ID: 33423661 [TBL] [Abstract][Full Text] [Related]
29. Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder. Andraka-Christou B Health Aff (Millwood); 2021 Jun; 40(6):920-927. PubMed ID: 34097509 [TBL] [Abstract][Full Text] [Related]
30. Opioid misuse viewed through person and place in the rural West. Voss MW; Yaugher AC; Atismé K; Campbell A J Opioid Manag; 2022; 18(2):151-159. PubMed ID: 35476884 [TBL] [Abstract][Full Text] [Related]
31. Opioid Initiation to Substance Use Treatment: "They Just Want to Feel Normal". Wilson M; Shaw MR; Roberts MLA Nurs Res; 2018; 67(5):369-378. PubMed ID: 30052592 [TBL] [Abstract][Full Text] [Related]
32. Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran. Noroozi A; Conigrave KM; Mirrahimi B; Bastani P; Charkhgard N; Salehi M; Narenjiha H; Vaziri A; Kebriaeezadeh A Drug Alcohol Rev; 2022 Feb; 41(2):419-429. PubMed ID: 34309108 [TBL] [Abstract][Full Text] [Related]
33. Medication Assisted Treatment Program Policies: Opinions of People in Treatment. Carter M; Boyd J; Bennett T; Baus A J Prim Care Community Health; 2023; 14():21501319231195606. PubMed ID: 37635696 [TBL] [Abstract][Full Text] [Related]
34. "You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia. Richard EL; Schalkoff CA; Piscalko HM; Brook DL; Sibley AL; Lancaster KE; Miller WC; Go VF Int J Drug Policy; 2020 Nov; 85():102704. PubMed ID: 32173274 [TBL] [Abstract][Full Text] [Related]
35. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Wyse JJ; Gordon AJ; Dobscha SK; Morasco BJ; Tiffany E; Drexler K; Sandbrink F; Lovejoy TI Subst Abus; 2018; 39(2):139-144. PubMed ID: 29595375 [TBL] [Abstract][Full Text] [Related]
36. Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary. McElrath K Subst Use Misuse; 2018 Jan; 53(2):334-343. PubMed ID: 28862903 [TBL] [Abstract][Full Text] [Related]
37. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Ma J; Bao YP; Wang RJ; Su MF; Liu MX; Li JQ; Degenhardt L; Farrell M; Blow FC; Ilgen M; Shi J; Lu L Mol Psychiatry; 2019 Dec; 24(12):1868-1883. PubMed ID: 29934549 [TBL] [Abstract][Full Text] [Related]
38. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review. Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172 [TBL] [Abstract][Full Text] [Related]
39. Treatment Retention in Opioid Dependent Clients Receiving Medication-Assisted Treatment: Six-Month Rate and Baseline Correlates. Fendrich M; Becker J; Ives M; Rodis E; Marín M Subst Use Misuse; 2021; 56(7):1018-1023. PubMed ID: 33843448 [TBL] [Abstract][Full Text] [Related]
40. Experiences of three states implementing the Medicaid health home model to address opioid use disorder-Case studies in Maryland, Rhode Island, and Vermont. Clemans-Cope L; Wishner JB; Allen EH; Lallemand N; Epstein M; Spillman BC J Subst Abuse Treat; 2017 Dec; 83():27-35. PubMed ID: 29129193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]